Medicare Enrolled
Dr. Habte Yimer, M.D.
Hematology · Tyler, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Yimer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Yimer? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Yimer
Dr. Habte Yimer is a hematology in Tyler, TX, with 20 years in practice. Based on federal Medicare data, Dr. Yimer performed 133,638 Medicare services across 5,953 unique beneficiaries.
Between the years covered by Open Payments, Dr. Yimer received a total of $827,252 from 74 pharmaceutical and/or device companies across 992 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Yimer is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 3% volume in TX$ $827,252 industry payments
Medicare Practice Summary
Medicare Utilization ↗133,638
Medicare services
Top 3% in TX for hematology
5,953
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,682 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 20,910 | $0 | $5 |
| Oxaliplatin chemotherapy injection | 18,560 | $0 | $33 |
| Nivolumab injection (Opdivo) | 12,460 | $23 | $76 |
| Pembrolizumab injection (Keytruda) | 12,200 | $42 | $136 |
| Paclitaxel chemotherapy injection | 9,582 | $0 | $8 |
| Contrast dye for imaging (iodine-based) | 9,254 | $0 | $3 |
| Darbepoetin injection (Aranesp) for anemia | 8,345 | $2 | $20 |
| Iron sucrose injection (Venofer) | 7,100 | $0 | $2 |
| Daratumumab injection (Darzalex) | 5,940 | $38 | $127 |
| Dexamethasone injection (steroid) | 3,093 | $0 | $1 |
| Injection, atropine sulfate, 0.01 mg | 2,640 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 2,160 | $18 | $66 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,970 | $24 | $155 |
| Immune globulin infusion (Octagam) | 1,930 | $34 | $233 |
| Blood draw (venipuncture) | 1,731 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,519 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,227 | $10 | $64 |
| Lactate dehydrogenase (enzyme) level | 1,033 | $6 | $31 |
| Injection, granisetron hydrochloride, 100 mcg | 1,030 | $0 | $24 |
| Injection, leucovorin calcium, per 50 mg | 798 | $3 | $25 |
| Office visit, established patient (30-39 min) | 742 | $91 | $368 |
| Immunoglobulin level test | 732 | $9 | $56 |
| Injection of additional new drug or substance into vein | 679 | $11 | $108 |
| Injection, fluorouracil, 500 mg | 609 | $2 | $13 |
| Anti-nausea injection (Aloxi/palonosetron) | 540 | $1 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 468 | $96 | $707 |
| Injection, carboplatin, 50 mg | 360 | $2 | $300 |
| Office visit, established patient (20-29 min) | 349 | $60 | $250 |
| Injection, potassium chloride, per 2 meq | 330 | $0 | $1 |
| Injection, irinotecan, 20 mg | 295 | $2 | $210 |
| Injection, zoledronic acid, 1 mg | 271 | $6 | $431 |
| Injection, cisplatin, powder or solution, 10 mg | 236 | $2 | $94 |
| Basic metabolic blood panel | 228 | $8 | $49 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 219 | $22 | $157 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 216 | $3 | $373 |
| Ferritin level test (iron stores) | 187 | $13 | $60 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 185 | $271 | $2,762 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 174 | $46 | $313 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 168 | $80 | $1,348 |
| Administration of additional new drug or substance into vein, 1 hour or less | 160 | $48 | $344 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 160 | $70 | $70 |
| Iron level test | 156 | $6 | $27 |
| Iron binding capacity test | 156 | $9 | $35 |
| Microscopic examination for white blood cells with manual cell count | 140 | $4 | $22 |
| Complete blood count (CBC), automated | 140 | $6 | $34 |
| Injection, magnesium sulfate, per 500 mg | 140 | $1 | $6 |
| Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg | 140 | $3 | $28 |
| Administration of chemotherapy into vein, each additional hour | 137 | $21 | $161 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 125 | $344 | $1,722 |
| Reticulated (young) platelet measurement | 123 | $35 | $143 |
| Injection, diphenhydramine hcl, up to 50 mg | 122 | $1 | $7 |
| Drug injection, under skin or into muscle | 113 | $10 | $96 |
| Magnesium level test | 109 | $7 | $29 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 98 | $55 | $211 |
| Ct scan of chest with contrast | 87 | $48 | $821 |
| Unclassified drugs | 73 | $1 | $8 |
| Infusion, normal saline solution , 1000 cc | 71 | $2 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 63 | $15 | $94 |
| New patient office visit, complex (60-74 min) | 63 | $156 | $709 |
| CT scan of abdomen and pelvis with contrast | 60 | $164 | $1,067 |
| Vitamin B-12 level test | 60 | $15 | $76 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 58 | $124 | $500 |
| PSA test (prostate cancer screening) | 48 | $18 | $94 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 46 | $16 | $100 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 46 | $91 | $657 |
| Carcinoembryonic antigen (cea) protein level | 44 | $19 | $99 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 42 | $178 | $700 |
| Irrigation of implanted venous access drug delivery device | 39 | $16 | $114 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 36 | $1,101 | $4,802 |
| Administration of additional new drug or substance into vein using push technique | 35 | $40 | $289 |
| Hospital follow-up visit, moderate complexity | 28 | $61 | $247 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 26 | $1 | $19 |
| Infusion into a vein for hydration, 31-60 minutes | 24 | $24 | $256 |
| Urea nitrogen level to assess kidney function, quantitative | 22 | $4 | $24 |
| Infusion into a vein for hydration, each additional hour | 22 | $10 | $75 |
| Manual urinalysis test with examination using microscope, non-automated | 21 | $4 | $26 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $24 | $145 |
| Drawing of blood for a medical problem | 21 | $53 | $264 |
| Blood creatinine level | 19 | $5 | $31 |
| CT scan of chest, without contrast | 18 | $40 | $686 |
| Ct scan of abdomen and pelvis before and after contrast | 17 | $190 | $1,413 |
| Ct scan of abdomen and pelvis without contrast | 14 | $74 | $560 |
| Application of on-body injector for under skin injection | 14 | $14 | $96 |
| Initial hospital admission, high complexity | 11 | $133 | $694 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
17.6% high complexity
75.2% medium
7.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$827,252
Total received (2018-2024)
Avg $118,179/year across 7 years
Top 2% in TX for hematology
74
Companies
992
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$703,979 (85.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$113,789 (13.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,485 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$122,659
2023$141,512
2022$116,510
2021$115,278
2020$92,725
2019$127,126
2018$111,442
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
BeiGene USA, Inc.
$139,615
Janssen Biotech, Inc.
$134,818
AstraZeneca Pharmaceuticals LP
$130,326
Amgen Inc.
$63,492
Karyopharm Therapeutics Inc.
$54,870
Takeda Pharmaceuticals U.S.A., Inc.
$46,791
Janssen Scientific Affairs, LLC
$35,490
ABBVIE INC.
$32,596
PFIZER INC.
$26,797
Lilly USA, LLC
$22,038
GlaxoSmithKline, LLC.
$21,850
Genmab U.S., Inc.
$20,631
AbbVie Inc.
$15,127
Seattle Genetics, Inc.
$9,876
Celgene Corporation
$9,158
Epizyme, Inc.,
$6,658
Incyte Corporation
$5,732
E.R. Squibb & Sons, L.L.C.
$5,728
GENZYME CORPORATION
$4,980
Genentech, Inc.
$4,162
Adaptive Biotechnologies Corporation
$4,145
Novartis Pharmaceuticals Corporation
$3,785
ADC Therapeutics America, Inc.
$2,977
BeiGene, Ltd.
$2,650
TAIHO ONCOLOGY, INC.
$2,343
Heron Therapeutics, Inc.
$2,240
Ipsen Biopharmaceuticals, Inc
$2,126
F. Hoffmann-La Roche AG
$2,052
Pharmacyclics LLC, An AbbVie Company
$1,945
MorphoSys, US Inc.
$1,770
CTI BioPharma Corp.
$1,757
Seagen Inc.
$1,481
Novocure Inc.
$1,272
Aadi Bioscience, Inc.
$1,000
G1 Therapeutics, Inc.
$893
Genentech USA, Inc.
$504
Regeneron Healthcare Solutions, Inc.
$276
Astellas Pharma US Inc
$249
Kite Pharma, Inc.
$248
Puma Biotechnology, Inc.
$246
Blueprint Medicines Corporation
$206
AbbVie, Inc.
$202
Merck Sharp & Dohme Corporation
$184
Tempus AI, Inc
$157
Exelixis Inc.
$141
Daiichi Sankyo Inc.
$140
Clovis Oncology, Inc.
$125
SOBI, INC
$123
Eisai Inc.
$119
Mirati Therapeutics, Inc.
$117
Rigel Pharmaceuticals, Inc.
$107
Synergy Pharmaceuticals Inc
$106
Alexion Pharmaceuticals, Inc.
$102
Bayer HealthCare Pharmaceuticals Inc.
$95
Stemline Therapeutics Inc.
$94
TESARO, Inc.
$73
JAZZ PHARMACEUTICALS INC.
$64
Gilead Sciences, Inc.
$51
ARRAY BIOPHARMA INC
$46
Boston Scientific Corporation
$33
Immunocore Limited
$29
Tactile Systems Technology Inc
$27
Pharmacosmos Therapeutics Inc.
$24
Sun Pharmaceutical Industries Inc.
$24
EMD Serono, Inc.
$22
Merck Sharp & Dohme LLC
$21
Pharmacyclics LLC, an AbbVie Company
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
SANOFI-AVENTIS U.S. LLC
$18
Sumitomo Pharma America, Inc.
$17
Allergan Inc.
$13
PUMA BIOTECHNOLOGY, INC.
$13
Taiho Oncology, Inc.
$12
Janssen Pharmaceuticals, Inc
$10
Top 3 companies account for 48.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Aliqopa · BAVENCIO · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · BYDUREON · CALQUENCE · COSELA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Epkinly · Erleada · FLEXITOUCH · FYARRO · Fedratinib · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · IMJUDO · INLYTA · INQOVI · Imbruvica · JAKAFI · JAYPIRCA · JEMPERLI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · KYMRIAH · Kyprolis · LIBTAYO · LONSURF · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NINLARO · Nerlynx · Non-Covered Product · OJJAARA · OPDIVO · ORGOVYX · Orserdu · Padcev · Perjeta · Pomalyst · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · TABRECTA · TAGRISSO · TAZVERIK · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Tazverik · Trulance · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · VYNDAQEL · VYXEOS · Vectibix · Vonjo · WATCHMAN Access System · XALKORI · XPOVIO · XT CDX · XTANDI · Xospata · YONSA · Yescarta · ZEJULA · ZENPEP · ZEPZELCA · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (85%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for hematology in TX.
Equivalent to $619 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
1
Per 100K population
0.4
County median income
$71,923
Nearest hospital
UT HEALTH EAST TEXAS TYLER REGIONAL HOSPITAL
3.0 mi
3.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Yimer is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), and high industry engagement (speaking/promotional, top 2%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Yimer experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Yimer performed 20,910 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Yimer receive payments from pharmaceutical companies?
Yes. Dr. Yimer received a total of $827,252 from 74 companies across 992 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Yimer's costs compare to other hematologys in Tyler?
Dr. Yimer's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Yimer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Tyler
Browse hematologys in Tyler ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in TX
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in TX
Which TX hematologys receive the most from drug and device companies.
By company
BeiGene USA, Inc. Payments to Doctors
See all physicians who received payments from BeiGene USA, Inc..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology